Serum selenium and risk of prostate cancer - A nested case-control study

Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA.
American Journal of Clinical Nutrition (Impact Factor: 6.77). 02/2007; 85(1):209-17.
Source: PubMed


Selenium is a potential chemopreventive agent against prostate cancer, whose chemoprotective effects are possibly mediated through the antioxidative properties of selenoenzymes. Interrelations with other antioxidative agents and oxidative stressors, such as smoking, are poorly understood.
The aims were to investigate the association between serum selenium and prostate cancer risk and to examine interactions with other antioxidants and tobacco use.
A nested case-control study was performed within the screening arm of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Serum selenium in prospectively collected samples was compared between 724 incident prostate cancer case subjects and 879 control subjects, frequency-matched for age, time since initial screen, and year of blood draw. The men were followed for up to 8 y.
Overall, serum selenium was not associated with prostate cancer risk (P for trend = 0.70); however, higher serum selenium was associated with lower risks in men reporting a high (more than the median: 28.0 IU/d) vitamin E intake [odds ratio (OR) for the highest compared with the lowest quartile of selenium: 0.58; 95% CI: 0.37, 0.91; P for trend = 0.05; P for interaction = 0.01] and in multivitamin users (OR for highest compared with the lowest quartile of selenium: 0.61; 95% CI: 0.36, 1.04; P for trend = 0.06; P for interaction = 0.05). Furthermore, among smokers, high serum selenium concentrations were related to reduced prostate cancer risk (OR for the highest compared with the lowest quartile of selenium: 0.65; 95% CI: 0.44, 0.97; P for trend = 0.09; P for interaction = 0.007).
Greater prediagnostic serum selenium concentrations were not associated with prostate cancer risk in this large cohort, although greater concentrations were associated with reduced prostate cancer risks in men who reported a high intake of vitamin E, in multivitamin users, and in smokers.

Download full-text


Available from: Gerald L Andriole, May 25, 2015
  • Source
    • "P trend = 0.58) (29). Recently, Peters et al. (2007) observed no inverse association between prediagnostic serum selenium concentration and the risk of prostate cancer in a large cohort study with 724 cases and 879 matched controls (OR = 0.84, 95% CI = 0.62–1.14, P trend = 0.70) (30). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Selenium is a potential chemopreventive agent against prostate cancer. This study sought to evaluate and compare the serum selenium level in men with newly diagnosed prostate cancer and noncancerous patients. Between 2005 and 2006, this prospective case-control study was performed on patients referred to Sina and Imam University hospitals, Tehran, Iran; it included 62 men with clinicopathologically confirmed diagnosis of prostate cancer (case group) and 68 men with no detectable prostate cancer [normal digital rectal examination and prostate-specific antigen (PSA) level] or any other malignant disease (control group). The serum selenium level was assessed using Zeeman graphite furnace atomic absorption spectrometer (Varian Company, Australia). The mean serum selenium level in the case and control group was 66.3 +/- 17.7 microg/l and 77.5 +/- 22.5 microg/l, respectively (P = 0.002). Serum selenium was inversely associated with prostate cancer risk. After adjustment for age, body mass index (BMI), and smoking, the odds ratio was 0.16 and 95% confidence intervals were 0.06 to 0.47 (P trendq = 0.001) comparing the highest with the lowest tertile (> or = 89.3 microg/l). No correlation was observed between serum selenium level and age, BMI, or PSA level. In conclusion, serum selenium levels in prostate cancer cases were lower than in controls, which supports the hypothesis that selenium may protect against prostate cancer.
    Nutrition and Cancer 03/2008; 60(2):171-6. DOI:10.1080/01635580701627277 · 2.32 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Abstract: An association between male and female sex hormones and selenium status has been reported in animals and humans. These relationships may be important in the regulation of selenium metabolism and relative to the possible use of selenium as an adjunct for treatment of hormone-related diseases such as breast cancer. The purpose of the first study was to examine the effect of estrogen status on the absorption, tissue distribution and metabolism of orally administered 75Se-selenite. Female Sprague Dawley rats were bilaterally ovariectomized and implanted with either a placebo pellet (OVX) or pellet with estradiol (OVX+E2) at 7 weeks of age. At 12 weeks of age, 60 [micro]Ci of 75Se as selenite was orally administered to each rat. Blood and organs were collected 1, 3, 6, and 24h after dosing. Although apparent absorption of 75Se was independent of estrogen status, hormone associated differences of 75Se levels were noted in plasma, RBC, liver, heart, kidney, spleen, brain, and thymus at certain times. Plasma selenoprotein P (SelP) in OVX+E2 group contained a greater percentage of administered 75Se at 3, 6 and 24h after gavage compared to OVX group. 75Se in plasma glutathione peroxidase (GPx) also was greater in OVX+E2 compared to OVX group at 24h. The second aim was to investigate the effect of estrogen status on selenium status in tissues, and on hepatic mRNA levels of SelP and GPx1. Estrogen significantly increased selenium status as measured by selenium concentration and GPx activity in plasma, liver, and brain. Selenium concentration in RBC was also increased by estrogen treatment. Selenium status in kidney and heart was independent of estrogen treatment. Real-time RT-PCR analysis demonstrated that both hepatic SelP and GPx1 mRNA were significantly increased by estrogen treatment. In conclusion, these results suggest that estrogen status affects distribution of ingested selenium in tissue- and time-dependent manners. Expression of hepatic SelP and GPx was regulated by estrogen at both mRNA and protein levels. As SelP has been shown to function as a selenium transporter, estrogen regulation of SelP may play an important role in whole body metabolism of selenium. Thesis (Ph. D.)--Ohio State University, 2007. System requirements: World Wide Web browser.
  • Source

    American Journal of Clinical Nutrition 01/2007; 85. · 6.77 Impact Factor
Show more